Prevention & lipidsResearch article
Global Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Events, 2023-2050
- Modelling study
- state-transition and demographic modelling
- 182 countries
- sensitivity analyses
Authors' conclusion
SPC therapies could substantially accelerate progress on cardiovascular disease mortality by increasing use of preventive drugs, especially in settings where uptake is currently low.
Study context
- Population
- Primary and secondary CVD prevention in 182 countries182 countries
- Comparison
- Single-pill combination (SPC) therapy scenarios vs non-SPC care
- Outcome
- Ischemic heart disease- and stroke-related deaths and nonfatal events prevented
- Follow-up
- 2023-2050
Main finding
As reported in the abstract
Deaths and cases prevented
| Group | Deaths prevented | Cases prevented |
|---|---|---|
| Targeted | up to 29 million | up to 51 million |
| Population | up to 72 million | up to 130 million |
Further findings
| Outcome | Targeted | Population | Non-SPC (current) care |
|---|---|---|---|
| Reduction in all-cause premature mortality | 2.0% | 3.2% | Not reported in the abstract |
Regional distribution
- Greatest share of events prevented in South and East Asia and the Pacific, because of population size
Original publication
Global Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Events, 2023-2050. J Am Coll Cardiol. Published 22 July 2025. doi:10.1016/j.jacc.2025.04.043
Summarised from the published abstract; every number is checked against it